Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 4 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Drug Price Cuts in Top Five Countries of Europe - Economic Overview | 10 | 5 |
| Healthcare Expenditure as a Percentage of GDP by Country | 10 | 1 |
| Health Expenditure Per Capita With Respect to GDP Per Capita | 11 | 1 |
| Pharmaceutical Expenditure Per Capita with Respect to GDP Per Capita | 12 | 1 |
| Pharmaceutical Expenditure as a Percentage of Healthcare Expenditure | 13 | 1 |
| Estimated Costs Paid by the Patient and Health Insurance System in the Total Reimbursed Pharmacy Market Value at Retail Prices | 14 | 1 |
| Drug Price Cuts in Top Five Countries of Europe Introductory Concepts | 15 | 12 |
| Industry Analysis | 15 | 1 |
| PEST Analysis of European Pharmaceutical Industry | 15 | 1 |
| Factors Responsible for the Differences in Drugs Prices in Top Five Countries of Europe | 16 | 1 |
| Supply Side and Demand Side Pharmaceutical Regulations in Europe | 16 | 2 |
| Drug Innovation Lag | 18 | 1 |
| Porters Five Forces Analysis | 19 | 1 |
| Role of Pharmacoeconomics in Pricing | 20 | 1 |
| Pricing Models | 21 | 1 |
| External Price Referencing or Internal Price Referencing | 21 | 1 |
| Internal Reference Pricing | 21 | 1 |
| Price Capping Regulations for Generic Pharmaceuticals | 21 | 1 |
| Use of Positive and Negative Formulary | 21 | 1 |
| Value-Based Pricing and Risk-Sharing Models | 22 | 1 |
| Tendering | 23 | 1 |
| VAT Rates for Outpatient Prescription Medicines | 24 | 1 |
| Regulatory Mechanisms in Top Five Countries of Europe | 25 | 2 |
| Drug Price Cuts in Top Five Countries of Europe - Recent Developments in Pricing of Drugs | 27 | 1 |
| EU Single Pricing | 27 | 1 |
| Parallel Trade Impact on Pricing | 27 | 1 |
| Drug Price Cuts in Top Five Countries of Europe Geographical Landscape | 28 | 34 |
| The UK | 28 | 1 |
| Macroeconomic Factors (PEST Analysis) | 28 | 1 |
| Healthcare System in Country | 29 | 1 |
| Total Expenditure on Health as a % of GDP | 29 | 1 |
| Public Expenditure on Health, % Total Expenditure on Health | 30 | 1 |
| Drug Pricing Authority and Procedures | 30 | 2 |
| Key Trends in Pricing of Drugs and Cuts | 32 | 1 |
| Flexible pricing options under the new PPRS Scheme | 32 | 1 |
| Value-based Pricing to Ensure the NHS Patients Get Access to Effective and Innovative Drugs | 33 | 1 |
| Major Challenges | 34 | 1 |
| France | 35 | 1 |
| Macroeconomic Factors (PEST Analysis) | 35 | 1 |
| Healthcare System in Country | 36 | 2 |
| Total Expenditure on Health as a % of GDP | 38 | 1 |
| Public Expenditure on Health, Percentage of Total Expenditure on Health | 39 | 1 |
| Drug Pricing Authority and Procedures | 40 | 1 |
| Concerned Authorities Involved in Pricing of Drugs | 40 | 2 |
| Key Trends in Pricing of Drugs and Cuts | 42 | 1 |
| Price Cuts by CEPS Have Resulted in Average Decrease of 10% in Pharmaceutical Drugs | 42 | 1 |
| CEPS to Monitor Clinical Benefit of the Drug | 42 | 1 |
| Call for Adjustments in Reforms as Generic Drugs Account for less than 15% | 43 | 1 |
| CEPS to Enforce the Reference Prices on Certain Branded Drugs | 43 | 1 |
| Reference Prices of Certain Generics were Adjusted in 2010 | 43 | 1 |
| Major Challenges | 44 | 1 |
| Germany | 44 | 1 |
| Macroeconomic Factors (PEST Analysis) | 44 | 1 |
| Healthcare System in Country | 45 | 1 |
| Total Expenditure on Health as a Percentage of GDP | 46 | 1 |
| Public Expenditure on Health, Percentage Total Expenditure on Health | 47 | 1 |
| Drug Pricing Authority and Procedures | 48 | 1 |
| Key Trends in Pricing of Drugs and Cuts | 48 | 1 |
| Three Main Components of AMNOG to Reduce the Prices of Patented Drugs | 49 | 1 |
| AMNOG Pricing Reforms, Manufacturers Pricing the Drug Post the Products Launch to be Restricted | 50 | 1 |
| Cost Benefit Analysis Mandatory For Newly Patented Medicines | 50 | 1 |
| Imposition of Price Freeze until 2013 at August 2009 Levels | 50 | 1 |
| Lowest Possible Price is seen as a Key Factor to Secure a Contract between Health Insurance Funds and Manufacturers of Generics | 50 | 1 |
| Current Challenges and Future Developments | 50 | 1 |
| Spain | 51 | 1 |
| Macroeconomic Factors (PEST Analysis) | 51 | 1 |
| Healthcare System in Spain | 51 | 1 |
| Total Expenditure on Health as a Percentage of GDP | 52 | 1 |
| Public Expenditure on Health, Percentage of Total Expenditure on Health | 53 | 1 |
| Drug Pricing Authority and Procedures | 53 | 1 |
| Key Trends in Pricing of Drugs and Cuts | 54 | 1 |
| Reference Prices to be Decided on Defined Daily Dose | 54 | 1 |
| Price Reductions in EU-authorized Generics to Increase from 20% to 30% | 54 | 1 |
| Price Discounts Inflicted on Patented and Orphan Medicines | 54 | 1 |
| Austerity Measures to Impose Average Price Cut of 25% on Generic Drugs | 54 | 1 |
| Demand Side Initiative to Impact Pricing of Pharmaceuticals | 55 | 1 |
| Current Challenges and Future Developments | 55 | 1 |
| Italy | 55 | 1 |
| Macroeconomic Factors (PEST Analysis) | 55 | 1 |
| Healthcare System in Country | 56 | 1 |
| Total Expenditure on Health as a Percentage of GDP | 57 | 1 |
| Public Expenditure on Health, Percentage of Total Expenditure on Health | 58 | 1 |
| Drug pricing authority and procedures | 58 | 1 |
| Key Trends in Pricing of Drugs and Cuts | 59 | 1 |
| Heavy Price Cuts in Generics and Off-patent Drugs | 59 | 1 |
| Proposed Margin Cuts of 3.6% on Reimbursed Medicines to be Split between Pharmacy and Drug Producer | 59 | 1 |
| Profitable Option for Companies Having Diabetes Products in Pipeline | 59 | 2 |
| Current Challenges and Future Developments | 61 | 1 |
| Reimbursement for the Cheapest Drug to Unfavorably Affect the Branded Drug Producers | 61 | 1 |
| Challenge for Generics Producers | 61 | 1 |
| Drug Price Cuts in Top Five Countries of Europe - Appendix | 62 | 5 |
| Market Definitions | 62 | 1 |
| Abbreviations | 62 | 2 |
| Sources | 64 | 1 |
| Research Methodology | 65 | 2 |
| Macroeconomic Factors (PEST Analysis) | 65 | 1 |
| Healthcare Systems | 65 | 1 |
| Key Trends in Pricing of Drugs and Cuts | 65 | 1 |
| Current Challenges and Future Developments | 66 | 1 |
| Contact Us | 66 | 1 |
| Disclaimer | 66 | 1 |